Healio
Healio

American Society of Retina Specialists Meeting
August 31, 2012
1 min read
Save

Single dose of minimally invasive treatment resolves some vitreomacular traction cases

LAS VEGAS — Ocriplasmin has a favorable safety profile and may provide a minimally invasive pharmacologic treatment for patients with vitreomacular traction and full-thickness macular hole, according to a speaker.

 Culling a subgroup of 266 patients with vitreomacular traction (VMT) at baseline from the two phase 3 MIVI-TRUST studies, Carl D. Regillo, MD, FACS, told colleagues here at the American Society of Retina Specialists meeting that 29.8% of the 188 patients in the ocriplasmin (ThromboGenics) treatment arm had resolution of vitreomacular adhesion at day 28 compared with 7.7% of 78 patients in the placebo group (P < .001). Ocriplasmin-treated patients received a single intravitreal dose of 125 µg.

Carl D. Regillo

Furthermore, ocriplasmin-treated patients with vitreomacular adhesion resolution demonstrated improvement in visual acuity over time.

“As expected, with VMT resolution at day 28, we see increasing proportion of patients gaining two to three or more lines over time through the study from day 7 out through month 6,” Regillo said.

Of 153 patients with macular hole treated with a single dose of ocriplasmin, nearly 60% had closure of the macular hole at day 28 compared with 16% in the placebo group, Regillo said. Macular holes between 250 µm and 400 µm successfully closed in 36.8% of patients compared with 5.3% of patients in the placebo group, but in patients with large macular holes greater than 400 µm, no macular holes closed.

  • Disclosure: Regillo is a consultant for and receives grant support from ThromboGenics.